JAK3: A two-faced player in hematological disorders |
| |
| Authors: | Melanie G. Cornejo Titus J. Boggon Thomas Mercher |
| |
| Affiliation: | 1. Department of Haematology, Second Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki (AUTH), Faculty of Medicine, Thessaloniki, Greece;2. Department of Haematology, First Department of Internal Medicine, AHEPA General Hospital, Aristotle University of Thessaloniki (AUTH), Faculty of Medicine, Thessaloniki, Greece;3. Department of Gastroenterology, First Propedeutic Department of Internal Medicine, AHEPA General Hospital, Aristotle University of Thessaloniki (AUTH), Faculty of Medicine, Thessaloniki, Greece;4. Department of Haematology, First Propedeutic Department of Internal Medicine, AHEPA General Hospital, Aristotle University of Thessaloniki (AUTH), Faculty of Medicine, Thessaloniki, Greece |
| |
| Abstract: | JAK3 is a non-receptor tyrosine kinase, predominantly expressed in hematopoietic cells and that has been implicated in the signal transduction of the common gamma chain subfamily of cytokine receptors. As a result, JAK3 plays an essential role in hematopoieisis during T cell development. JAK3 inactivating mutations result in immunodeficiency syndromes (SCID) in both humans and mice. Recent data indicate that abnormal activation of JAK3 due to activating mutations is also found in human hematological malignancies, including acute megakaryoblastic leukemia (AMKL) and cutaneous T cell lymphoma (CTCL). After a brief summary of the JAK3 structure and function, we will review the evidence on the emerging role of JAK3 activation in hematological malignancies that warrant further studies to test the relevance of specific inhibition of JAK3 as a therapeutic approach to these challenging clinical entities. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
